CTNM Contineum Therapeutics Forecast, Technical & Fundamental Analysis
Contineum Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the development of oral small-molecule therapies for neurological, inflammatory, and immunological conditions... Show more
CTNM is expected to report earnings to rise 10.26% to -43 cents per share on November 11
Q3'26
Est.
$-0.43
Q1'26
Beat
by $0.46
Q4'25
Beat
by $0.16
Q3'25
Beat
by $0.15
Q2'25
Missed
by $0.34
The last earnings report on May 05 showed earnings per share of -38 cents, beating the estimate of -85 cents. With 194.40K shares outstanding, the current market capitalization sits at 646.71M.
A.I.dvisor indicates that over the last year, CTNM has been loosely correlated with PMN. These tickers have moved in lockstep 34% of the time. This A.I.-generated data suggests there is some statistical probability that if CTNM jumps, then PMN could also see price increases.
The Moving Average Convergence Divergence (MACD) for CTNM turned positive on August 20, 2026. Looking at past instances where CTNM's MACD turned positive, the stock continued to rise in of 21 cases over the following month. The odds of a continued upward trend are .
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on August 19, 2026. You may want to consider a long position or call options on CTNM as a result. In of 42 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where CTNM advanced for three days, in of 129 cases, the price rose further within the following month. The odds of a continued upward trend are .
Bearish Trend Analysis
The RSI Oscillator demonstrated that the stock has entered the overbought zone. This may point to a price pull-back soon.
The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CTNM declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
CTNM broke above its upper Bollinger Band on August 21, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for CTNM entered a downward trend on August 05, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. CTNM’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.698) is normal, around the industry mean (20.145). P/E Ratio (26.395) is within average values for comparable stocks, (22.992). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (3.861). Dividend Yield (0.000) settles around the average of (0.018) among similar stocks. P/S Ratio (10.101) is also within normal values, averaging (444.692).
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CTNM’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 92, placing this stock worse than average.
